Veritas is taking preventive genomic medicine to Repsol’s entire workforce in Spain.￼ November 21, 2022 by elizarios Leave a Comment Veritas and Repsol have signed an agreement that will allow Repsol employees to access precision medicine through the genetics services of Veritas.The agreement provides for access by Repsol’s employees, initially in Spain, under particularly advantageous conditions, to the entire range of preventive genetics services from Veritas. Thanks to the genetics information obtained, this will enable them to prevent the onset of certain diseases or minimise their effects, and a personalised medical management in each case.According to recent studies presented at the latest European Society of Human Genetics (ESHG) conference in June 2022, 20% of people present genetic variants that increase their risk of suffering from certain diseases, and 8 in every 10 people are carriers of a disease that they could pass on to their children. Veritas, a letsgetchecked company, has reached an agreement with Repsol to offer its entire workforce in Spain access to preventive genomic medicine. The partnership provides for access by Repsol’s employees in Spain, under particularly advantageous conditions, to the entire range of preventive genetics services from Veritas. It reinforces the focus of the energy multinational in preserving the health of its workers, through the prevention and early diagnosis of diseases. Disease prevention According to recent studies presented at the latest European Society of Human Genetics (ESHG) conference in June 2022, 20% of people present genetic variants that increase their risk of suffering from certain diseases, and 8 in every 10 people are carriers of a disease that they could pass on to their children. This information is on our DNA, from the day we are born. Thus, genomics has become a key tool in preventive medicine and Veritas pioneered genome sequencing and interpretation for preventive purposes. Additionally, it has developed a variety of specific panels related to specific pathologies, in areas such as oncology and cardiology. Thanks to this agreement, Repsol employees will be able to access Veritas’ preventive genetics services, and will have this key information, that could prevent or minimise the effects of diseases or illnesses that they have a genetic predisposition to. “With this agreement, Repsol joins a group of large global companies that are incorporating genetics into the active care of their employees’ health, offering them a state-of-the-art tool that will enable them to prevent and avoid certain diseases for which they have a genetic predisposition and improve their health check-ups. It will even help them to personalise their medical treatment”, notes Javier de Echevarría, CEO of Veritas. Portfolio of preventive medicine genetics services Repsol employees and their first-degree relatives will be able to undergo tests such as myGenome, the most comprehensive service in its category. Thanks to whole genome sequencing and its clinical interpretation, they will be able to find out whether they have a genetic predisposition to suffering from more than 650 diseases, in order to avoid them, prevent them or detect them early. They will also have the option to use myNewborn, the neonatal screening service from Veritas for the detection of up to 390 diseases that present themselves during childhood, to prevent their onset or to treat them from the beginning. myGeneticRisk, a genetic service which enables more than 140 genes to be studied, discovering the risk of suffering a cardiovascular disease or cancer. There are also more specific tests such as myCardio, which studies the predisposition to suffering from a hereditary cardiovascular disease through an exhaustive analysis of more than 100 genes, or myCancerRisk which is focussed on the main types of hereditary cancer, thanks to the study of more than 40 genes with sufficient scientific evidence. About Veritas Veritas Intercontinental was founded in 2018 to lead the expansion of the brand and genetics services of Veritas in Europe, Latin America, the Middle East and Japan. In 2020, Veritas Intercontinental opened its laboratory in Europe. With this new expansion, the company now offers a comprehensive portfolio which includes the myGenome service, exome-based genetic testing and genetics services relating to maternal-foetal medicine. In March 2022, Veritas announced it will form part of LetsGetChecked, a global healthcare solutions company with offices in Dublin and New York. About Repsol Repsol is a global multi-energy company which is leading the energy transition and has set the goal of zero net emissions by 2050. It is present throughout the energy value chain, employs 24,000 people, distributes its products in almost 100 countries and boasts 24 million customers. Repsol produces an average of approximately 650,000 barrels of oil each day and has one of the most efficient refining systems in Europe. The company is transforming its seven industrial complexes in Spain, Portugal and Peru into multi-energy hubs through state-of-the-art projects that will reduce their carbon footprint and will enable them to become a leader in the production of renewable hydrogen and sustainable fuels in 2030. It can satisfy any energy and mobility need of consumers, with a customer-focussed offer. It is leading the development of sustainable solutions for mobility, with increasingly efficient fuels, electric charging, biofuels, AutoGas or vehicular natural gas. Furthermore, it is major player in the electricity and gas market, with 1.2 million customers and renewable electricity generation assets with a total installed capacity of 1.1GW. In order to achieve zero net emissions by 2050, Repsol is committed to a model that incorporates all decarbonisation technologies, based on improving efficiency, increasing its capacity to generate renewable electricity, the production of fuels with a low carbon footprint, the development of new solutions for customers, the circular economy and boosting cutting-edge projects to reduce the industry’s carbon footprint.